Publication details
Cenobamát v léčbě farmakorezistentní fokální epilepsie
| Title in English | Cenobamate in the treatment of the farmacoresistant focal epilepsy |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Ceska a slovenska neurologie a neurochirurgie |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.csnn.eu/en/journals/czech-and-slovak-neurology-and-neurosurgery/2023-2-8/cenobamate-in-the-treatment-of-the-farmacoresistant-focal-epilepsy-134283 |
| Doi | http://dx.doi.org/10.48095/cccsnn2023153 |
| Keywords | Cenobamate; farmacoresistant focal epilepsy |
| Description | A new anti-seizure medication (ASM) cenobamate was launched in the Czech Republic in January 2023. In Slovakia, cenobamate was launched in August 2022. In the United States, it has been registered since 2019 under the trade name XCOPRI®, the European Medicines Agency (EMA) granted cenobamate a marketing authorisation in March 2021 and in EU countries it is marketed under the trade name ONTOZRY®. It is indicated for the adjunctive treatment of focal seizures with or without transition to bilateral tonic-clonic convulsions in adult patients with epilepsy without adequate control despite prior treatment with at least two anti-seizure medications. This meets the International League Against Epilepsy (ILAE) definition of pharmacoresistant epilepsy. |